Drug Profile
Small interfering RNA encapsulated nanocells - EnGeneIC
Alternative Names: EGFREDVPLK; EGFREDVRRM1Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator EnGeneIC
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adrenocortical carcinoma; Solid tumours
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Adrenocortical-carcinoma(Late-stage disease) in Australia (IV)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (IV)
- 29 Sep 2017 Phase-I clinical trials in Adrenocortical carcinoma (Late-stage disease) in Australia (IV) (EnGeneIC website, September 2017)